Project Grant R01HL172834
- This federal Project Grant award of $683,048.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital in Columbus, OH. The research aims to investigate the cellular and molecular mechanisms underlying left ventricular noncompaction cardiomyopathy (LVNC), a rare and potentially fatal heart condition characterized by excessive myocardial trabeculae. The project will...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with completion scheduled for May 31, 2029. This research project delivers a comparative mechanistic study examining gene regulatory and structural pathways in lamin A/C (LMNA)-related dilated cardiomyopathy (LMNA-DCM), a severe...
- This Project Grant award of $746,800 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research conducted by Baylor College of Medicine to define the major signaling mechanisms controlling spontaneous cardiomyocyte (CM) proliferation during the neonatal stage. The research objectives include identifying and characterizing the CD36 transmembrane scavenger receptor pathway's role in regulating CM proliferation in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $134,998 to J. David Gladstone Institutes on July 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research investigating the cellular and molecular mechanisms that enable cardiac progenitors to construct the linear heart tube during embryonic development. This K99/R00 award, which extends through May 31, 2027, is led by Principal Investigator Dr....
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a $865,286 project grant (CFDA 93.837, Cardiovascular Diseases Research) effective August 1, 2025, through June 30, 2029, to develop a high-resolution spatiotemporal lineage map of cardiac development. The primary deliverable is a comprehensive mapping of how cardiac progenitor cells differentiate into specialized heart cell types, utilizing advanced lineage tracing, spatial,...
- This federal Project Grant award, titled "NICHE-SPECIFIC ENDOTHELIAL MECHANISMS REGULATING THE EXTRAVASATION OF HEMATOPOIETIC STEM CELLS", was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The $734,607 grant, awarded on May 1, 2025, supports research at Boston Medical Center Corporation to elucidate the key endothelial mechanisms that direct circulating hematopoietic stem cells (HSCs) across the blood vessel...
- This federal Project Grant award of $160,000.00 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research by Baylor College of Medicine to elucidate the morphogenetic and molecular mechanisms by which the genes RERE and SPEN contribute to the development of congenital heart defects associated with 1p36 deletion syndrome. The research aims to determine how SPEN deficiency...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $118,632 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 11, 2025, with a completion date of July 31, 2027. The grant supports research investigating the role of matrifibrocytes in fibrotic-like responses during myxomatous heart valve disease (MVD) progression. The research utilizes a Marfan syndrome...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of Columbia University in the City of New York $761,262 under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant commencing September 1, 2025, and concluding June 30, 2029. The research investigation will be conducted at Columbia's Health Sciences Division in New York, New York. This award funds a four-year basic science research project examining the protective mechanisms...
MECHANISMS OF SIGNALING INTERACTION BETWEEN ENDOCARDIUM AND MYOCARDIUM - COMMUNICATION BETWEEN THE MYOCARDIUM AND ENDOCARDIUM, SEPARATED BY A LAYER OF CARDIAC JELLY, IS ESSENTIAL FOR HEART MORPHOGENESIS, ESPECIALLY TRABECULAR FORMATION. TRABECULAE ARE SHEET-LIKE STRUCTURES THAT INCREASE SURFACE AREA WHEN THE CORONARY SYSTEM IS NOT YET ESTABLISHED. LACK OF TRABECULATION CAUSES EMBRYONIC DEMISE, AND EXCESS TRABECULATION CAUSES LEFT VENTRICULAR NONCOMPACTION CARDIOMYOPATHY (LVNC). THE MORTALITY OF PATIENTS WITH LVNC RANGES FROM 5% TO 47%. DESPITE ITS CLINICAL IMPORTANCE, THE MECHANISMS OF TRABECULATION ARE NOT FULLY UNDERSTOOD, AND HOW THE COMMUNICATION BETWEEN CARDIOMYOCYTES (CMS) IN THE MYOCARDIUM AND ENDOCARDIAL CELLS (ECS) IN THE ENDOCARDIUM IS ACHIEVED AND REGULATES TRABECULATION IS NOT FULLY KNOWN. SOME LIGANDS AND RECEPTORS ENGAGED IN MYOCARDIUM-ENDOCARDIUM COMMUNICATION ARE LOCALIZED TO MEMBRANES OF CMS AND ECS, YET HOW LIGAND/RECEPTOR-MEDIATED INTERACTIONS OCCUR ACROSS THE CARDIAC JELLY HAS YET TO BE DECIPHERED. UNLIKE DIRECT CELL-CELL INTERACTIONS, DISTANT CELL-CELL COMMUNICATION CAN BE ACHIEVED VIA SEVERAL MECHANISMS, INCLUDING DIFFUSIBLE FACTORS SUCH AS MORPHOGENS AND RECENTLY DISCOVERED NOVEL MICROSTRUCTURES SUCH AS TUNNELING NANOTUBES (TNTS) IN CULTURED MAMMALIAN CELLS OR CYTONEMES IN FLIES. WHETHER A MICROSTRUCTURE THAT REGULATES SIGNALING INTERACTION AMONG DISTANT CELLS IN VIVO IN MAMMALS WAS NOT REPORTED, AND WHETHER A SIMILAR STRUCTURE REGULATES THE SIGNALING INTERACTION BETWEEN THE CMS AND ECS DURING CARDIOVASCULAR MORPHOGENESIS IS UNKNOWN. VIA GENETIC LABELING, ELECTRON MICROSCOPY (EM), AND CRYOGENIC-EM (CRYO-EM), OUR PRELIMINARY DATA SHOW A NANOTUBE-LIKE MICROSTRUCTURE, WHICH IS NAMED SIGNALING BRIDGES (SBS), EXTEND FROM CMS ACROSS CARDIAC JELLY TO REACH ECS TEMPORALLY; SB IS SUFFICIENT TO ACTIVATE NOTCH SIGNALING; DISRUPTION OF SB BY DELETING CDC42 OR BY CHEMICALS HINDERS NOTCH ACTIVATION AND ALTERS CM CELLULAR BEHAVIORS, RESULTING IN TRABECULATION DEFECTS. THESE NOVEL PRELIMINARY DATA ESTABLISH THE ESSENTIAL ROLES OF SBS IN SIGNAL TRANSDUCTION AND TRABECULATION DURING CARDIAC MORPHOGENESIS; HOWEVER, DETAILS REGARDING SB STRUCTURE, FUNCTION, AND REGULATORY MECHANISMS IMPACTING HEART MORPHOGENESIS REMAIN UNKNOWN. WE HYPOTHESIZE THAT SBS ARE REQUIRED FOR THE SIGNALING INTERACTION BETWEEN THE CMS AND ECS TO CONTROL CELLULAR BEHAVIORS DURING TRABECULATION (FIG. 1). THREE AIMS ARE PROPOSED: WE WILL APPLY VARIOUS ELECTRON MICROSCOPY TO DETERMINE THE ULTRASTRUCTURE AND FUNCTION OF SBS IN AIM I; INTERROGATE HOW SBS TRANSDUCE SIGNALING BETWEEN ECS AND CMS IN AIM II; ELUCIDATE HOW SB MEDIATED INTERACTION REGULATE TRABECULAR MORPHOGENESIS IN AIM III. COMPLETING THE PROPOSED STUDIES WILL DETERMINE HOW SIGNAL INTERACTION BETWEEN THE CMS AND ECS IS ACHIEVED AND HOW SBS REGULATE CELLULAR BEHAVIOR AND TRABECULAR FORMATION. THE DISCOVERY OF SBS AND THEIR FUNCTIONS IN VIVO OPENS NEW AVENUES FOR UNDERSTANDING INTERCELLULAR INTERACTION DURING CARDIAC MORPHOGENESIS. SUCCESSFUL COMPLETION OF THIS STUDY WILL EXPAND OUR UNDERSTANDING OF THE ETIOLOGY OF TRABECULATION DEFECTS AND, ULTIMATELY, THE ETIOLOGY OF LVNC, THEREBY PROVIDING A BASE FOR DEVELOPING NEW THERAPEUTIC STRATEGIES FOR MITIGATING LVNC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $661.9k | 8/12/25 | ||
| Not listed | $675.6k | 7/10/24 |